TACSTD2 and breast cancer: The anti-Trop2 ADC (Trodelvy TM, sacituzumab govitecan, SG), which has been approved in metastatic BC and metastatic UC, proves Trop2 to be a valid therapeutic target in tumor treatment (11–13).